In dismal economic times, lower-cost product alternatives that save consumers money are supposed to thrive, or at least hold their own. But in the midst of a global financial meltdown, even the market for generic drugs is faltering. The worldwide sales growth rate of me-too medicines slowed to a crawl in the 12 months ended September 2008, rising a weak 3.6% over the previous 12-month period, IMS Health reported.